Precision Psychedelic Therapy
Pioneering a precision approach to psychedelics, targeting precise drug blood levels in patients

Exploring innovative solutions in psychedelic drug development for enhanced patient care.

Clinical-stage biotechnology

Tryptamine Therapeutics Limited is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments.

IV infusion of psilocin

Tryptamine Therapeutics intends to accomplish this through the development of an IV infusion of psilocin (the active metabolite of psilocybin) which addresses many of the current limitations associated with orally administered psilocybin used by the majority of competitors in the field.

Neuropsychiatric disorders

Tryp’s lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy.

A Precision Approach to Psychedelic Medicine
With a focus on:

Tryp Therapeutics is driven by patient outcomes – addressing areas of unmet medical need with proven potential.

Innovation at our core

We are pioneering proprietary formulations for synthetic psilocybin and psilocin and novel techniques for its manufacture. We are developing dosing and delivery methods for psychedelics to reduce the time spent by patients in the psychedelic state, thereby improving their experience.

Global patents

We are pursuing global patents at every opportunity, with a foundational provisional patent application already filed and many more to come.

Skills to scale

Our senior leaders have proven abilities to build and scale across a variety of relevant categories. Our management team has an innate ability to create and nurture collaborations with the best scientific talent from leading universities and research institutions around the world.

Healthier, happier patients

Millions of people suffer from health conditions like chronic pain, for which few or no effective treatment options currently exist. Each one of these conditions is a humanitarian need — and an unaddressed market opportunity. Our pharmaceutical focus on psilocybin has the potential to transform the treatment of chronic pain and other indications, and relieve the suffering of millions of patients.

ASX Filings

Get the latest information for investors.

Read the latest investor information on Tryptamine Therapeutics Limited at the Australian Stock Exchange.
“By allowing rapid initiation and termination of the psychedelic experience, as well as providing highly refined control over the depth and duration of that experience, I believe TRP-8803 has a very strong potential to shift the treatment paradigm for fibromyalgia and binge eating disorder, as well as certain types of depression, pain and obsessive-compulsive disorders.”
— Robin Carhart-Harris, Ph.D. Chairman, Scientific Advisory Board

Recent news and events